GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clal Biotechnology Industries Ltd (XTAE:CBI) » Definitions » Change In Payables And Accrued Expense

Clal Biotechnology Industries (XTAE:CBI) Change In Payables And Accrued Expense : ₪0.00 Mil (TTM As of Dec. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Clal Biotechnology Industries Change In Payables And Accrued Expense?

Clal Biotechnology Industries's Change In Payables And Accrued Expense for the quarter that ended in Dec. 2024 was ₪0.00 Mil. It means Clal Biotechnology Industries's Accounts Payable & Accrued Expense stayed the same from Jun. 2024 to Dec. 2024 .

Clal Biotechnology Industries's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2024 was ₪0.00 Mil. It means Clal Biotechnology Industries's Accounts Payable & Accrued Expense stayed the same from Dec. 2023 to Dec. 2024 .


Clal Biotechnology Industries Change In Payables And Accrued Expense Historical Data

The historical data trend for Clal Biotechnology Industries's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clal Biotechnology Industries Change In Payables And Accrued Expense Chart

Clal Biotechnology Industries Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Change In Payables And Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Clal Biotechnology Industries Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Change In Payables And Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Clal Biotechnology Industries Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₪0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Clal Biotechnology Industries Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Clal Biotechnology Industries's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Clal Biotechnology Industries Business Description

Traded in Other Exchanges
N/A
Address
Azrieli Center, Triangle Building, 45th Floor, Tel Aviv, ISR, 67023
Clal Biotechnology Industries Ltd is a life sciences investment company. The company invests in companies ranging from seed to maturity, both public and private. Its portfolio of investments includes from heavy industry to biotechnology, hi-tech and energy companies.

Clal Biotechnology Industries Headlines

From GuruFocus

Does the Increase in Volatility Signal a Dangerous Market Environment?

By Chuck Carnevale Chuck Carnevale 11-11-2016

This Warren Buffett Bargain Stock Is Good For A Double

By Jonathan Poland Jonathan Poland 05-27-2015

Chairman, CEO, CFO Purchase Shares in McDermott

By PRNewswire PRNewswire 11-07-2018

CBI: Former Buffett Stock Worth Buying Now

By Jonathan Poland Jonathan Poland 06-29-2017

Van Den Berg Almost Sells Out 4 Stakes in 1st Quarter

By David Goodloe David Goodloe 04-20-2016

CB&I Announces DPC Technology Award in China

By PRNewswire PRNewswire 04-03-2018